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Summary
Similarities between the pathobiology of aortic stenosis (AS) and atherosclerosis have led 
to the concept that pharmacological strategies effective in atherosclerosis might attenuate 
valvular inflammation. 
The objective of this study was to assess how angiotensin-converting enzyme inhibitors (ACEIs) 
might affect valvular expression of coagulation and inflammatory proteins in AS. 
We studied 111 advanced AS patients (62 males, aged 63.3±11.2 years) undergoing valve re-
placement. Plasma levels, valvular expression and mRNA transcripts of tissue factor (TF), TF 
pathway inhibitor (TFPI), prothrombin, along with C-reactive protein (CRP) and interleukin-6 
(IL-6) were evaluated. 
TF-, TFPI-, CRP and prothrombin valvular expression was not related to demographics, con-
comitant diseases or plasma TF, free-TFPI or IL-6. ACEIs-treated patients (n=37), mainly due to 
hypertension (n=24, 65%), showed decreased areas for valvular TF (13.64±6.43 vs. 18.05±6.81%, 
p=0.03), TFPI (32.6±7.8 vs. 49.15±9.5%, p<0.001), prothrombin (23.47±1.93 vs. 26.61±1.4%, p<0.001), 
CRP (0.75 [0-9] vs. 1.4 [0-8]%, p=0.009), and IL-6 (3.2±0.65 vs. 6.4±1.83%, p<0.001) compared with 
non-ACEIs patients. Similarly, patients treated with ACEIs showed lower mRNA expression 
of TF (1.22±0.47 vs. 2.27±1.42, p=0.041), prothrombin (0.13±0.07 vs. 0.81±0.37, p<0.001), CRP 
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INTRODUCTION
Aortic stenosis (AS) has a prevalence of 1-3% in patients 
older than 65 years [20]. The development and progres-
sion of AS is an active inflammatory process, sharing 
several common characteristics with atherosclerosis, 
including disruption of the basement membrane, sub-
endothelial accumulation of intracellular lipids, and 
molecular mediators of calcification, together with infil-
tration of the inflammatory cells and activation of local 
and systemic inflammation [15, 25]. The concept of AS as 
an atherosclerosis-like process is supported by a number 
of studies showing that the development of AS is asso-
ciated with cardiovascular risk factors such as smoking, 
hypercholesterolemia or arterial hypertension [19].  The 
clinical and histological similarities between the active 
pathobiology of AS and atherosclerosis have led to the 
therapeutic concept that pharmacological strategies 
effective in atherosclerosis, such as treatment with angi-
otensin-converting enzyme inhibitors (ACEIs), might 
reduce the progression of AS. However, available ACEIs 
studies yielded conflicting results, including negative 
findings from a large prospective and randomized trial 
[24]. The presence of angiotensin-converting enzyme 
(ACE) and angiotensin II, which cannot be found in nor-
mal valve tissue, has been demonstrated in sclerotic aor-
tic valves [22]. This observation suggests a role for the 
renin-angiotensin system in the pathogenesis of aortic 
valve lesions. It is known that ACEIs, apart from being 
very effective in the current treatment of arterial hyper-
tension therapy [3, 30], exhibit beneficial effects beyond 
lowering blood pressure, including anti-inflammatory 
[10]  and antithrombotic [7]  effects. 
Observations made in loco within human aortic valves 
[2, 17, 18] and in an in vivo animal model of aortic valve 
disease [14] demonstrated increased expression of tis-
sue factor (TF), a major initiator of blood coagulation in 
vivo, associated with macrophage infiltration [2, 18] of 
the stenotic aortic valve leaflets. It has been shown that 
TF expression within aortic valves is positively associ-
ated with transvalvular pressure gradient in AS patients, 
which might contribute to AS progression [18]. Moreo-
ver, interleukin-6 (IL-6) [29] and C-reactive protein (CRP) 
[26] were found within aortic valves and the amounts of 
these pro-inflammatory proteins correlated with the AS 
severity [29].
We sought to investigate whether ACEIs influence the 
expression of TF, TF pathway inhibitor (TFPI) and pro-
thrombin as well as CRP and IL-6 in patients with 
advanced AS without clinically overt atherosclerotic 
vascular disease.
MATERIALS AND METHODS 
Patients
A total of 111 consecutive patients (62 men and 49 
women) undergoing isolated elective aortic valve 
replacement for severe AS (mean transvalvular gradi-
ent ≥40 mmHg) were recruited. The exclusion criteria 
were: diabetes mellitus, acute infection, renal failure, 
Valsalva sinus aneurysmor rheumatic AS, angiographi-
cally documented epicardial artery stenosis >20% diame-
ter, known cancer, autoimmune disorders, endocarditis, 
previous cardiac surgery, a history of myocardial infarc-
tion, stroke, venous thromboembolism or bleeding [13]. 
Patients who required additional surgical intervention 
or had other heart defects were ineligible.
Information on the presence or absence of cardio-
vascular risk factors, including arterial hyperten-
sion, hyperlipidemia, smoking, and use of statin, 
ACEIs, β-adrenolytic drugs and acetylsalicylic acid was 
obtained before surgery. Smoking was defined as the use 
of 1 or more cigarettes per day. Arterial hypertension 
was diagnosed based on a history of hypertension (blood 
pressure >140/90 mmHg) or preadmission antihyperten-
sive treatment. Hyperlipidemia was diagnosed based on 
In patients with severe AS, ACEIs use is associated with lower expression of valvular proteins 
involved in coagulation and inflammation, thus ACEIs therapy could be important in altering 
atherosclerosis-like processes within stenotic aortic valves.
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blocked. Primary adequate monoclonal antibodies were 
applied overnight at 4°C against human TF (R&D Sys-
tems, Inc., Minneapolis, USA), TFPI (American Diagnos-
tica Inc., Stamford, CT, USA), prothrombin (Hyphen Bio 
Med, Neuville-Sur-Oise, France), CRP (Santa Cruz Bio-
technology, Inc., CA, US) or inflammation marker – IL-6 
(Abcam, Cambridge, UK). Primary antibodies were fol-
lowed by the corresponding secondary antibodies conju-
gated with fluorochrome (Abcam, Cambridge, UK) or by 
the avidin-biotin complex immunoperoxidase according 
to manufacturer’s instructions (Santa Cruz Biotechnol-
ogy Inc., CA, US). Diamninobenzidine was used as the 
chromogen. A negative control (without primary anti-
body incubation) was included routinely. Sections were 
viewed in Zeiss, Berlin, Germany. Photomicrographs 
taken using a Canon A640 camera were analyzed with 
image analysis software Cell Analyst [11].
Nucleic acid extraction
Human valves obtained during aortic valve replacement 
were immediately placed in RNAlater (Qiagen, Chats-
worth, CA) and stored in liquid nitrogen. Frozen valve 
cups were pulverized using Mikro-Dismembrator S (Sar-
torius Stedim Biotech, Germany). Total RNA was isolated 
with the RNeasy Mini kit, according to the manufactur-
er’s protocols (Qiagen, Chatsworth, CA) and digested with 
DNase (DNase I recombinant, RNase-Free, Qiagen, Chats-
worth, CA). The RNA concentration was estimated by 
A260 measurement, and the samples were stored at -80°C.
Quantification of TF, prothrombin, CRP and 
IL-6transcripts by real-time PCR
A total of 1µg of RNA from each individual valve cups 
was reverse transcribed to single strain cDNA using High 
Capacity RNA-to-cDNA Master Mix (Applied Biosystems) 
at 25°C for 5 min, 42°C for 30 min followed by 85°C for 5 
min. The cDNA was amplified with TaqMan Gene Expres-
sion Assays containing both primers and probe (TF, 
assay ID Hs01076032_m1; prothrombin, Hs00354679_m1; 
IL-6, Hs00985639_m1; and CRP, Hs00265044_m1) on an 
ABI PRISM® 7900HT Fast Real–Time PCR System (Applied 
Biosystems). The assays were from Applied Biosystems 
as Inventoried or Made-to-Order.
Beta-actin (Hs99999903_m1, human ACTB Endogenous 
Control FAM/MGB Probe, Non-Primer Limited; Applied 
Biosystems) was used as a housekeeping gene. To ana-
lyze the obtained data, the comparative threshold cycle 
(CT) method was applied [5]. In brief, the amount of 
a target gen, normalized to ACTB, and relative to a cal-
ibrator (normal valve leaflet), is given by 2-∆∆CT, where 
∆∆CT = ∆CT of a sample (the CT of the target gene of AS 
valves subtracted from the CT of ACTB) -∆CT of calibrator.
Statistical analysis 
Values are expressed as mean (SD) or median (inter-
quartile range) or otherwise stated. The Kolmogo-
medical records, statin therapy, or total cholesterol 5.2 
mmol/l or more. Renal failure was diagnosed based on 
having at least 2 random fasting creatinine levels of>110 
µmol/l for male and >80 µmol/l for female.
Patients were classified as receiving ACEIs if they were 
receiving medication at least for 6 months (ACEIs+ group). 
The remaining patients were classified as the ACEIs-
group. The Local Ethical Committee in Krakow approved 
the study, and the participants provided informed con-
sent in accordance with the Declaration of Helsinki.
Echocardiography
A transthoracic echocardiography was performed 
in each patient using a MargotMac 5000 ultrasound 
machine prior to surgery by using conventional tech-
niques in accordance with the guidelines of European 
Society of Cardiology (ESC) and Polish Cardiac Society 
[12].  The aortic valve area (AVA) was calculated using 
the standard continuity equation [28]. The transvalvu-
lar gradient was measured by Doppler echocardiography 
using the modified Bernoulli equation [28]. 
Laboratory tests
Fasting venous blood was drawn from patients 24 hours 
before surgery between 7 and 9 AM. Citrated blood sam-
ples (9:1 of0.129 M citrate) were centrifuged at 2000 g  at 
20°C for 20 min and stored in aliquots at -80°C until anal-
ysis. Lipid profile, glucose, and creatinine were assayed 
by routine laboratory techniques. High-sensitivity CRP 
was determined using immunoturbidimetry (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA). Commer-
cially available ELISA tests were used to determine in cit-
rated plasma TF (American Diagnostica Inc., Stamford, 
CT, USA),and free (f)-TFPI (Diagnostica Stago, Asnieres, 
France)and in serum IL-6 (R&D Systems, Inc., Minneap-
olis, USA) according to manufacturer’s instructions. All 
measurements were performed by technicians blinded 
to the origin of the samples. Intra-assay and inter-assay 
coefficients of variation were <8%.
Analysis of aortic valves
Diseased aortic valves were collected during surgery for 
valve replacement. Valves embedded in Tissue Tec-OCT 
compound (Sakura, Torrance, CA, USA) for tissue cryo-
preservation were cryosectioned (10 µm thick) onto 
SuperFrost slides (Menzel-Glaser, Germany) by a Leica 
Jung CM 3000 cryostat. Sections were taken transversely 
from the mid of the leaflet and from commissural areas. 
Slides were stored at -20°C until immunostaining.
Immunostaining analysis
Immunostaining was performed on adjacent sections 
of aortic valves as described before [17, 18]. In brief, 
endogenous alkaline phosphatase and peroxidase activ-
ities were quenched and unspecific background was 
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(Figure 1A). Of note, the areas positive for TFPI were 2.9-
fold larger than for TF (49.24 ± 11.61%vs. 18.98 ± 9.84%). 
Prothrombin antigen was detected in 25.96 ± 12.57% of 
the total valve area and was colocalized with both TF 
and TFPI (Figure 1B, C). However, areas positive for pro-
thrombin were also visible in other, TF-free, regions. 
There were no age-, gender-, or smoking-related dif-
ferences in the percentage of valvular areas positive 
for TF, TFPI, or prothrombin. We observed associations 
between both TF- and TFPI-positive areas and the pro-
thrombin-positive area (r=0.67, p=0.004; r=0.71, p=0.014, 
respectively). We also found positive correlations of TF 
and TFPI expression with maximal (r=0.62, p<0.0001; 
r=0.72, p=0.02, respectively) and mean (r=0.53, p=0.0002; 
r=0.56, p=0.03, respectively) gradients and an inverse 
correlation with AVA(r=-0.63, p<0.0001, r=-0.71, p=0.004), 
while LVEF showed an inverse association of borderline 
significance with TFPI (r=-0.50, p=0.056). Positive cor-
relations of prothrombin valvular areas with maximal 
(r=0.51, p=0.024) and mean (r=0.57, p=0.019) transvalvu-
lar pressure gradients and an inverse correlation with 
AVA (r=-0.58, p=0.011) were also observed.
Valvular mRNA expression
Analysis of relative gene expression data using real-time 
quantitative PCR has shown up-regulation of TF (2.49 
± 1.42), prothrombin (0.87 ± 0.31), CRP (1.05 ± 1.0) and 
IL-6 (8.04 ± 6.25) valvular mRNA expression within the 
AS valves. TF mRNA expression was positively associated 
with prothrombin mRNA expression (r=0.69, p=0.041) 
and plasma CRP (r=0.32, p=0.027), but not with plasma 
IL-6. However, a positive correlation between prothrom-
bin mRNA and IL-6 mRNA expression (r=0.62, p=0.045) 
was observed. Moreover, an inverse association between 
expression of TF mRNA and AVA (r= -0.38, p=0.012) was 
noted. 
ACEIs
Among 111  AS patients, there were 37 (33.3%) subjects 
treated with ACEIs, mainly due to hypertension (n=24, 
65%). The following ACEIs were used: enalapril in 14 
(37.8%) patients, ramipril in 15 (40.5%), and captopril in 8 
(21.6%) patients. Statins were administered in 36 (32.4%) 
patients. No ACEIs-associated differences were observed 
in demographic, clinical and echocardiographic variables 
compared with patients not treated with ACEIs (Table 2). 
Compared with ACEIs- (n=74, 66.7%), ACEIs+ patients were 
characterized by decreased percentage of valvular immu-
noreactive areas for TF (13.64 ± 6.43 vs. 18.05 ± 6.81%, 
p=0.03), TFPI (32.6 ± 7.8 vs.49.15 ± 9.5%, p<0.001), pro-
thrombin (23.47 ± 1.93 vs. 26.61 ± 1.4%, p<0.001), CRP (0.75 
[0-9] vs. 1.4 [0-8]%, p=0.009), and IL-6 (3.2 ± 0.65 vs. 6.4 ± 
1.83, p<0.001) (Figure2A). Valvular mRNA expression for 
TF (1.22 ± 0.47 vs. 2.27 ± 1.42, p=0.04), prothrombin (0.13 
± 0.07 vs. 0.81 ± 0.37, p<0.001), CRP (0.73 ± 0.29 vs. 1.25 ± 
0.69, p=0.04), and IL-6 (7.6 ± 5.2 vs. 13.7 ± 7.3, p=0.046) was 
lower in ACEIs-treated patieACEIs-treatedompared with 
the non-ACEIs- grounon-ACEIsure 2B). 
rov-Smirnov test was used to assess conformity with 
a normal distribution. Pair-wise comparisons were made 
using Tukey’s test for continuous variables and the χ2 
test for proportions. The Mann-Whitney U test was used 
to compare non-normally distributed variables between 
two groups. Spearman’s correlation coefficient was 
calculated to evaluate associations between variables. 
A value of p<0.05 was considered statistically significant.
RESULTS
Baseline characteristics of 111 patients are shown in 
Table 1.
Immunofluorescence
Immunofluorescent staining of aortic valves showed the 
abundance of TF antigen at the aortic side of the leaf-
lets, colocalizing in 64 ± 7.15 % with TFPI-positive areas 
Table 1. Baseline characteristics of AS patients
Variables AS (n=111)
Male, n (%) 62 (56)
Age, years 63.3 ±11.2
Body mass index (kg/m2) 28.7±5.1
Risk factors
Arterial hypertension, n (%) 24 (21.6)
Hypercholesterolemia, n (%) 37 (33.3)
Current smoking, n (%) 11 (9.9)
Obesity, n (%) 35 (31.5)
Renal failure, n (%) 23 (20.7)
Echocardiography
Mean aortic gradient (mmHg) 58.8±23




Beta-adrenolytic drugs, n (%) 52 (46.8)
Acetylsalicylic acid, n (%) 45 (40.5)
ACE inhibitors, n (%) 37 (33.3)
Statins, n (%) 36 (32.4)
Laboratory parameters
C-reactive protein (mg/l) 4.7 [0.5-66.8]
Interleukin-6 (ng/ml) 8.5 [0.3-30.1]
Tissue Factor (pg/ml) 123.9 [27-192.3]
Free Tissue Factor Pathway Inhibitor (ng/
ml)
40.6 [14.3-103]
Data are given as mean±SD, median (IQR) or number 
(percentage). LVEF, left ventricular ejection fraction; 
AVA, aortic valve area. Obesity was defined as body mass 
index >30 kg/m2
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The biological mechanisms leading to AS and their simi-
larities to atherosclerosis have typified two of the lead-
ing candidates for drug therapy in AS patients, namely 
statins and ACEIs. However, the available studies have 
failed to show the beneficial effects of statin therapy 
on AS progression [4, 9]. Our findings provided evi-
dence that ACEIs could affect the valvular processes 
leading to valve calcification, at least in subjects with 
advanced AS, and they probably retard AS progression 
[10]. Our rationale for ACEIs-induced alterations in val-
vular expression of the coagulation and inflammatory 
proteins are based on several lines of evidence. Firstly, 
AS valves express Ang II and ACE [22]. Available stud-
ies have implicated the renin-angiotensin system, par-
ticularly ACE, Ang II and the Ang II type receptor, in 
DISCUSSION
The current study shows that long-term ACEIs use is 
associated with reduced expression of crucial proteins 
involved in both inflammation and coagulation within 
aortic valves in AS patients. Our major findings can be 
summarized as follows: 
• ACEIs use is associated with a decreased percentage of 
valvular TF-, TFPI-, prothrombin-, CRP- and IL-6-positive 
areas within stenotic valves and 
• mRNA expression of valvular TF and prothrombin 
together with CRP and IL-6 are reduced by ACEIs on 
a long-term treatment.
Fig. 1. Representative micrographs of immunoreactive areas of (A), tissue factor (red) colocalized with tissue factor pathway inhibitor (green); (B), prothrombin; and 
(C) tissue factor (red) colocalized with prothrombin (green). Colocalized areas of each factor are stained orange. (*) aortic side of the leaflet. Bar, 500 µm
Table 2. Baseline characteristics of ACEI+ vs. ACEI- patients
ACEI+ (n=37) ACEI- (n=74) P value
Male, n (%) 21 (56.8) 41 (55.4) 0.99
Age, years 65.9±9.8 62.8±11.48 0.75
Body mass index (kg/m2) 30.4±4.4 27.6±4.8 0.37
Echocardiography
Mean aortic gradient (mmHg) 56.1±17.3 58±22.4 0.71
Maximum aortic gradient (mmHg) 86.9±24.6 93.01±24.7 0.52
LVEF (%) 54.35±12.5 57.38±12.9 0.31
AVA (cm2) 0.74±0.2 0.74±0.2 0.91
Treatment
Beta-adrenolytic drugs, n (%) 18 (48.6) 34 (45.9) 0.84
Acetylsalicylic acid, n (%) 14 (37.8) 31 (41.9) 0.84
Statins, n (%) 17 (45.9) 19 (25.7) 0.052
Laboratory parameters
C-reactive protein (mg/l) 4.55 [0.62-51.9] 4.9 [0.5-66.8] 0.71
Interleukin-6 (ng/ml) 8.26 [1.09-17.7] 8.64 [0.31-30.07] 0.82
Tissue Factor (pg/ml) 93.08 [27-133.8] 133.08 [104.6-192.3] 0.06
Free TFPI (ng/ml) 52.3 [22.8-95.1] 41 [14.33-103] 0.01
Data are given as mean±SD, median (IQR) or number (percentage). LVEF, left ventricular ejection fraction; AVA, aortic 
valve area; Free TFPI, Free Tissue Factor Pathway Inhibitor
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monocytes by endotoxin induces translocation of c-Rel 
/p65 heterodimers from the cytoplasm into the nucleus. 
Binding of the heterodimers to a regulatory κB element 
within the TF promoter induces its transcriptional acti-
vation [23]. Some ACEIs, like captopril [16] have been 
shown to largely prevent c-Rel/p65 translocation to the 
promoter region of the gene encoding for TF in mono-
cytes. Thus, the decreased expression of TF on both pro-
tein and mRNA levels in the present study may be linked 
with monocyte-angiotensin II biosynthesis/activity sup-
pression.
Stenotic leaflets from patients treated with ACEIs were 
also characterized by decreased IL-6 expression on 
both protein and mRNA levels. Macrophages, which are 
numerous within stenotic valves and are responsible for 
IL-6 secretion, are released in response to angiotensin II 
[6]. Côté et al. showed that IL-6 induced by angiotensin 
II plays a key role in fibrotic response, leading to fibro-
calcification of the aortic valves [6].
STUDY LIMITATIONS
First, the presence of antigens expressed within aortic 
valves was determined using a semi-quantitative anal-
ysis system, which could reduce the precision of the 
results. However, a large number of the images analyzed 
per one valve likely provided reliable results. Addi-
tional analysis, such as ELISA tests performed on the 
valve homogenates, has not been performed. Second, 
the present study was focused on the valves obtained 
from patients with severe AS. Therefore, our observa-
tions cannot be extrapolated from subjects with mild 
AS or those with aortic sclerosis. Third, it is unclear 
whether there are any differences between various 
ACEIs, in terms of modulation of the expression of the 
proteins studied. mRNA analysis for TFPI has not been 
performed.
AS progression, through stimulation of inflammation 
and macrophage activation, cholesterol accumulation, 
impaired fibrinolysis and increased oxidant stress [10]. 
Moreover, ACEIs have been shown to reduce TF expres-
sion in human blood monocytes [16]. Our study shows 
that TF-lowering effect of ACEIs could be potent enough 
to be demonstrated also in aortic valve tissue obtained 
from AS patients. Taubman et al. demonstrated that 
after angiotensin stimulation of rat aortas vascular 
smooth muscle cells, the expression of TF mRNA was 
short-lived and lasted 1 hour after stimulation [27].
Given the data showing reduced calcium accumulation 
in aortic valves of AS patients receiving ACEIs [21] and 
those on the links between calcium and macrophage 
infiltration in the AS vales [2], one might suggest that 
ACEIs can suppress macrophage activity within the aor-
tic valves and thus they may alter prothrombotic and 
proinflammatory responses within the diseased valve. 
It has been demonstrated in an animal model that olm-
esartan, an angiotensin type I receptor antagonist, 
reduces atherosclerotic changes in aortic valves by pre-
serving endothelial cells integrity and inhibiting trans 
differentiation into myofibroblasts or into osteoblasts in 
valve leaflets [1]. It has also been shown that inhibition 
of ACE activity attenuated TF expression and microvas-
cular remodeling in left ventricle myocardium cells of 
mice [31]. Finally, blood pressure lowering effect indi-
rectly reduces the pressure overload of the left ventri-
cle and potentially reduces the mechanical stress and 
strain on the aortic valve [8]. The present data might 
indicate that the administration of ACEIs is likely to 
confer potent clinical benefits in AS patients. However, 
the mechanisms underlying ACEIs action in AS are still 
unclear. Most likely, macrophages which are an integral 
component of stenotic valves and express Ang I and Ang 
II may play an important role, similarly to atherosclero-
sis [16]. Induction of TF gene expression in macrophages 
is regulated by transcriptional factors. Stimulation of 
Fig. 2. Quantitative analysis of (A) immunostained prothrombin, tissue factor (TF), tissue factor pathway inhibitor (TFPI), C-reactive protein (CRP) and interleukin-6 
(IL-6); (B) mRNA levels of TF, prothrombin, CRP and IL-6 within aortic valves in patients receiving (ACEI+, n=37; black columns) or non-receiving (ACEI-, n=74; gray 
columns) angiotensin-converting enzyme inhibitors. Bars represent means±SD or median (IQR)
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ACEIs therapy could be important in altering atheroscle-
rosis-like processes within human stenotic aortic valves, 
generates new hypotheses to be tested in an interven-
tional study with a long-term follow-up.
In conclusion, we have shown that ACEIs use is associ-
ated with lower expression of TF, prothrombin, CRP and 
IL-6 within aortic valves on both protein and mRNA lev-
els in AS patients. Our study, indicating that long-term 
Fig. 3. Interleukin-6 (IL-6) mRNA expression in VICs cultures treated with angiotensin I (panel A) or II (panels B and C) and with an appropriate inhibitor
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